Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
A sudden increase of serum-free light chains was associated with treatment-induced tumor lysis syndrome in multiple myeloma, suggesting a possible risk factor.
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
[Breast Cancer: Targets and Therapy] This research examines possible core biomarkers for triple-negative breast cancer.
A review of HER2-positive breast cancer, including etiology, diagnosis, and treatments.
Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
